{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:56:19Z","timestamp":1789577779879,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG-22089"],"award-info":[{"award-number":["IG-22089"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Associazione Italiana Leucemie Linfomi e Mielomi (AIL)","award":["N.A."],"award-info":[{"award-number":["N.A."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mature T-cell lymphomas (MTCLs) represent a heterogeneous group of aggressive non-Hodgkin lymphomas comprising different entities. Anthracycline-based regimens are considered the standard of care in the front-line treatment. However, responses to these approaches have been neither adequate nor durable, and new treatment strategies are urgently needed to improve survival. Genomic instability is a common feature of cancer cells and can be caused by aberrations in the DNA damage response (DDR) and DNA repair mechanisms. Consistently, molecules involved in DDR are being targeted to successfully sensitize cancer cells to chemotherapy. Recent studies showed that some hematological malignancies display constitutive DNA damage and intrinsic DDR activation, but these features have not been investigated yet in MTCLs. In this study, we employed a panel of malignant T cell lines, and we report for the first time the characterization of intrinsic DNA damage and basal DDR activation in preclinical models in T-cell lymphoma. Moreover, we report the efficacy of targeting the apical kinase ATM using the inhibitor AZD0156, in combination with standard chemotherapy to promote apoptotic cell death. These findings suggest that DDR is an attractive pathway to be pharmacologically targeted when developing novel therapies and improving MTCL patients\u2019 outcomes.<\/jats:p>","DOI":"10.3390\/ijms23073834","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:28:39Z","timestamp":1648675719000},"page":"3834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma"],"prefix":"10.3390","volume":"23","author":[{"given":"Martina","family":"Magni","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paolizzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Monfrini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Vella","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"},{"name":"School of Medicine, Universit\u00e0 degli Studi di Milano, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-1757","authenticated-orcid":false,"given":"Cristiana","family":"Carniti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Cancer Research. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.beha.2018.07.010","article-title":"Peripheral T-cell lymphoma\u2014Are we making progress?","volume":"31","author":"Khan","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100889","DOI":"10.1016\/j.blre.2021.100889","article-title":"T time: Emerging and new therapies for peripheral T-cell lymphoma","volume":"52","author":"Mina","year":"2021","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41416-019-0557-8","article-title":"Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma","volume":"121","author":"Magni","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA Damage as a Source of Genomic Instability in Cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers","volume":"20","author":"Cottini","year":"2014","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2011.94","article-title":"Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX","volume":"25","author":"Walters","year":"2011","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.18632\/oncotarget.2720","article-title":"Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma","volume":"6","author":"Derenzini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41375-021-01347-6","article-title":"Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma","volume":"36","author":"Rossi","year":"2022","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1080\/10428194.2017.1283031","article-title":"Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression","volume":"58","author":"Rebechi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/10428194.2018.1498494","article-title":"Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"60","author":"Popp","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","article-title":"The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1, 3-dihydro-2 H-imidazo[4, 5-c]quinolin-2-one)","volume":"61","author":"Pike","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: Potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Faulhaber, E.M., Jost, T., Symank, J., Scheper, J., B\u00fcrkel, F., Fietkau, R., Hecht, M., and Distel, L. (2021). Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. Genes, 12.","DOI":"10.3390\/genes12060925"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"\u03b3h2AX: A sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/gad.333237.119","article-title":"53BP1: A DSB escort","volume":"34","author":"Mirman","year":"2020","journal-title":"Genes Dev"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/em.2850250303","article-title":"DNA-damaging effect of cyclophosphamide on human blood cells in vivo and in vitro studied with the single-cell gel test (comet assay)","volume":"25","author":"Hartmann","year":"1995","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_29","first-page":"84","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_30","first-page":"95","article-title":"Molecular mechanisms of etoposide","volume":"14","author":"Montecucco","year":"2015","journal-title":"EXCLI J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/bjmg-2016-0002","article-title":"Assessment of genotoxicity of vincristine, vinblastine and vinorelbine in human cultured lymphocytes: A comparative study","volume":"19","author":"Mhaidat","year":"2016","journal-title":"Balkan J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/toxsci\/kft259","article-title":"Dose-Response Modeling of Etoposide-Induced DNA Damage Response","volume":"137","author":"Li","year":"2014","journal-title":"Toxicol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.dnarep.2012.08.006","article-title":"Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells","volume":"11","author":"Korwek","year":"2012","journal-title":"DNA Repair (Amst.)"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/mutage\/get017","article-title":"DNA damage-independent apoptosis induced by curcumin in normal resting human T cells and leukaemic Jurkat cells","volume":"28","author":"Korwek","year":"2013","journal-title":"Mutagenesis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","article-title":"Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer","volume":"12","author":"Batey","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.3324\/haematol.2016.143768","article-title":"C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas","volume":"101","author":"Manso","year":"2016","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jclinpath-2018-205216","article-title":"p16","volume":"71","author":"Serra","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102090","DOI":"10.1016\/j.ctrv.2020.102090","article-title":"Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences","volume":"90","author":"Carrassa","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-18-0919","article-title":"DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas","volume":"18","author":"Restelli","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"A094","DOI":"10.1158\/1535-7163.TARG-17-A094","article-title":"Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)","volume":"17","author":"Abida","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1038\/ncomms14290","article-title":"THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors","volume":"8","author":"Cayrol","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17817","DOI":"10.18632\/oncotarget.4417","article-title":"CCAR2\/DBC1 is required for Chk2-dependent KAP1 phosphorylation and repair of DNA damage","volume":"6","author":"Magni","year":"2015","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:47:05Z","timestamp":1760136425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23073834"],"URL":"https:\/\/doi.org\/10.3390\/ijms23073834","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}